Global Oral Antiviral Market Size study, by Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, Others) by Drug Class (Protease inhibitors, Reverse transcriptase inhibitors, Others) by Distribution Channel (Hospital pharmacies, Drug stor

Global Oral Antiviral Market Size study, by Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, Others) by Drug Class (Protease inhibitors, Reverse transcriptase inhibitors, Others) by Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers) and Regional Forecasts 2022-2032

Global Oral Antiviral Market is valued approximately USD 36.7 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 2.10% over the forecast period 2024-2032. Oral antiviral drugs, taken by mouth, are pivotal in combating viral infections. They function by impeding viral replication, entry into host cells, or release from infected cells. These drugs serve as frontline treatments for various viral infections including influenza, herpes simplex virus, hepatitis B and C, HIV, among others. Additionally, they play a crucial role in both preventing and treating infections, tailored to specific circumstances. Some are utilized preventively, particularly for individuals at high risk of contracting viruses such as HIV. Furthermore, rising investing in research and development to expand the range of oral antiviral drugs available. This included developing new drugs targeting a broader spectrum of viruses are gaining attention towards Global Oral Antiviral Market.

The Global Oral Antiviral Market is driven by rising prevalence of viral infections, such as hepatitis, influenza, and HIV, is generating increased demand for effective oral antiviral drugs. This demand is further fueled by the growing availability of improved healthcare infrastructure, particularly in emerging markets. In addition, rising advancements and innovations within the pharmaceutical sector geared towards manufacturing oral antiviral drugs present a promising opportunity for the oral antiviral market. The uptick in approvals for a range of oral antiviral agents, alongside an expanding array of clinical trials conducted by key players worldwide, is poised to positively influence market growth. However, absence of favorable reimbursement policies and side effects of the oral antiviral drugs is going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the Global Oral Antiviral market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in terms of revenue. The upsurge in viral infections such as HIV and hepatitis C, coupled with the presence of key players offering oral antiviral solutions and the bolstering of healthcare infrastructure, are driving the of growth in the oral antiviral market in North America. Moreover, the Asia-Pacific region is poised for fastest expansion due to heightened investments in oral antiviral agent development, a rise in cases of viral infections, and an increasing number of pipeline medications tailored for treating such infections. These factors collectively propel the growth trajectory of the oral antiviral market throughout the forecast period 2024-2032.

Major market player included in this report are:
Bristol-Myers Squibb Company
Johnson & Johnson Services Inc.
AbbVie Inc.
Amneal Pharmaceuticals LLC
Gilead Sciences, Inc.
Viatris Inc.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc

The detailed segments and sub-segment of the market are explained below:

By Indication
Hepatitis
Human Immunodeficiency Virus (HIV)
Influenza
Others
By Drug Class
Protease inhibitors
Reverse transcriptase inhibitors
Others
By Distribution Channel
Hospital pharmacies
Drug store and retail pharmacies
Online providers

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.